Flagship Biosciences hires Tom Turi, Ph.D. as CSO
Flagship Biosciences hired industry veteran Tom Turi as Chief Scientific Officer. Tom will help grow the company’s spatial biology and biomarker analytics business and expand strategic partnerships supporting customers’ therapeutic development and clinical trials needs. BroadOak recently provided growth equity funding to Flagship Biosciences. Flagship’s full press release is below. BROOMFIELD, Colo., September 27, 2022—Flagship […]
Flagship Acquires Interpace’s Pharma Services Business
Following BroadOak’s growth equity investment in Flagship Biosciences, Flagship Biosciences has acquired Interpace Pharma Solutions, a provider of cytogenetic, molecular pathology, and genomic profiling solutions. Bill Snider and Aaron Fisher are joining the Board of Flagship Biosciences. The full press release is below. BROOMFIELD, Colo., Aug. 31, 2022 /PRNewswire/ — Flagship Biosciences, Inc., a leader […]
BroadOak Increases Investment in Halo Labs
BroadOak joined Agilent Technologies, a global leader in life sciences and diagnostics, to increase its investment in Halo Labs as part of the company’s Series C round of growth financing. Halo Labs uses state-of-the-art optics and image processing to support drug development. The funding will help Halo Labs grow its product and solutions portfolio for […]
BroadOak Invests in Microsize
BroadOak invested in Microsize, a CDMO specializing in micronization and particle size control, as part of its launch as an independent business. The full press release is below. Microsize Launched as Independent Pharma Services Company Meets the Growing Need for US-Based API Solubility and Bioavailability Enhancement Services QUAKERTOWN, Pa. — Microsize today announced the launch […]
BRT Sells to Medix Biochemica
BroadOak Capital Partners advised Bioresource Technology (“BRT”) on the sale of the company to Medix Biochemica. BRT is a leading provider of high-quality base matrices and other critical raw materials for the IVD industry. The full press release is below. Bioresource Technology joins Medix Biochemica Group Medix Biochemica broadens its capabilities in diagnostic base matrices […]
BroadOak Announces Investment in LabVoice
BroadOak invested in LabVoice, a company that leverages device, software, and customized workflows to enable the automated lab. Led by entrepreneurs Frederic Bost and Matt Hahn, the pair have deep experience building market-leading scientific software companies. LabVoice’s offering results in optimal lab processes that create proven efficiencies for customers. Newly commercial, the company has already […]
MyChem Sells To Maravai LifeSciences
BroadOak Partners advises MyChem, LLC on the sale of the company to Maravai LIfeSciences (NASDAQ: MRVI). MyChem is a leading provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics, and research markets. The full press release is below. MyChem’s nucleotide synthesis methods are highly complementary to Maravai’s TriLink mRNA technologies Increases capabilities […]
JMI Announces Sale to Element Materials Technology
BroadOak Capital Partners advised JMI Laboratories (“JMI”) on the sale of the company to Element Materials Technology (“Element”). JMI is a leading provider of antimicrobial drug development, molecular testing, clinical trial support, and surveillance services to biotech and pharmaceutical companies. The full press release is below. Element strengthens pharmaceutical and biotech capability with JMI Laboratories […]
BroadOak Provides $8M Loan to Interpace Biosciences
BroadOak Capital Partners provided a senior term loan to refinance debt held by Interpace’s private equity stockholders, Ampersand Capital and 1315 Capital. Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. The full press release is […]